<DOC>
	<DOCNO>NCT02949011</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy single , oral dose S-033188 compare placebo measure time improvement influenza symptom patient influenza present within 48 hour symptom onset .</brief_summary>
	<brief_title>Study S-033188 Compared With Placebo Oseltamivir Patients With Influenza High Risk Influenza Complications</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>1 . Patients legal guardian provide write informed consent participate study voluntary basis . For adolescent patient , inform consent/assent voluntary participation obtain accordance local requirement . 2 . Male female patient ≥ 12 year time signing informed consent/assent form . 3 . Patients duration influenza symptom confirm follow : 1 . Fever ≥ 38ºC ( axillary ) predose examination within 4 hour prior antipyretic take 2 . At least 1 follow general respiratory symptom associate influenza present severity moderate great : . General symptom ( headache , feverishness chill , muscle joint pain , fatigue ) ii . Respiratory symptom ( cough , sore throat , nasal congestion ) 4 . The time interval onset symptom predose examination 48 hour less . The onset symptom define either : 1 . Time first increase body temperature ( increase least 1ºC normal body temperature ) 2 . Time patient experience least 1 new general respiratory symptom 5 . If woman childbearing potential , agree use highly effective method contraception 3 month first dose study drug 6 . Patients consider high risk* influenza complication due presence least 1 follow inclusion criterion : 1 . Asthma chronic lung disease ( chronic obstructive pulmonary disease cystic fibrosis ) 2 . Endocrine disorder ( include diabetes mellitus ) 3 . Residents longterm care facility ( eg , nurse home ) 4 . Compromised immune system ( include patient receive corticosteroid exceed 20 mg prednisolone equivalent , patient treat human immunodeficiency virus ( HIV ) infection CD4 count &gt; 350 cells/mm³ within last 6 month ) 5 . Neurological neurodevelopmental disorder ( include disorder brain , spinal cord , peripheral nerve , muscle , eg , cerebral palsy , epilepsy [ seizure disorder ] , stroke , muscular dystrophy , spinal cord injury ) 6 . Heart disease ( congenital heart disease , congestive heart failure , coronary artery disease ) , exclude hypertension without heartrelated symptom 7 . Adults age ≥ 65 year 8 . American Indians Alaskan Natives 9 . Blood disorder ( sickle cell disease ) 10 . Metabolic disorder ( inherit metabolic disorder mitochondrial disorder ) 11 . Morbid obesity ( body mass index ≥ 40 ) 12 . Women within 2 week postpartum breastfeed 1 . Patients severe influenza virus infection require inpatient treatment . 2 . Patients know allergy oseltamivir ( Tamiflu® ) . 3 . Patients unable swallow tablet capsule . 4 . Patients previously receive S033188 . 5 . Patients weigh ≤ 40 kg . 6 . Patients expose investigational drug within 30 day prior predose examination . 7 . Women pregnant , breastfeeding , positive pregnancy test predose examination . The following female patient documentation either b need undergo pregnancy test predose examination : 1 . Postmenopausal woman ( defined cessation regular menstrual period 2 year confirm folliclestimulating hormone test ) 2 . Women surgically sterile hysterectomy , bilateral oophorectomy , tubal ligation 8 . Patients concurrent infection predose examination require systemic antimicrobial therapy . 9 . Patients liver disease associate hepatic impairment . 10 . Patients cancer within last 5 year ( unless nonmelanoma skin cancer ) . 11 . Patients untreated HIV infection treat HIV infection CD4 count 350 cells/mm3 last 6 month . 12 . Patients immunosuppression follow organ bone marrow transplant . 13 . Patients exceed 20 mg prednisolone equivalent dose chronic systemic corticosteroid . 14 . Patients receive peramivir , laninamivir , oseltamivir , zanamivir , rimantadine , umifenovir amantadine within 30 day prior predose examination . 15 . Patients receive investigational monoclonal antibody viral disease last year . 16 . Patients know creatinine clearance ≤ 60 mL/min . 17 . Patients , opinion investigator , would unlikely comply require study visit , selfassessments , intervention</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tamiflu®</keyword>
	<keyword>Influenza</keyword>
	<keyword>Oseltamivir</keyword>
	<keyword>Flu</keyword>
	<keyword>S-033188</keyword>
</DOC>